G 207
Embryonal Tumor
Gregory K. Friedman, MDgene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Embryonal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
BLEOMYCIN Children's Oncology Group | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Children's Oncology Group | Phase 3 | BB |
ETOPOSIDE Children's Oncology Group | Phase 3 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
G 207 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →